SGLT2 Inhibitors in Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the last two-decades, there has been a substantial increase in the number of medications licenced for management of T2DM which reduce cardiovascular and renal risk, and enhance weight loss [58-60].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab560 · Cited by 256
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242
Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050255 · Cited by 242
Self-citationGeorgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044359 · Cited by 117
Research works printed but not linked: 48
- Von Mrig, 1836, Observations sur les proprietes febrifuges de la phloridzine, Bull Soc Med Gand, 75
- von Mering, 1885, Uber kunstlichen diabetes, Centralbl Med Wiss, 23, 531
- Chasis, 1933, The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man, J Clin Invest, 12, 1083, 10.1172/JCI100559 · DOI · Paper page
- Alvarado, 1962, Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro, Biochim Biophys Acta, 56, 170, 10.1016/0006-3002(62)90543-7 · DOI · Paper page
- Vick, 1973, Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs, Am J Physiol, 224, 552, 10.1152/ajplegacy.1973.224.3.552 · DOI
- Ehrenkranz, 2005, Phlorizin: a review, Diabetes Metab Res Rev, 21, 31, 10.1002/dmrr.532 · DOI · Paper page
- Oku, 1999, T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes, Diabetes, 48, 1794, 10.2337/diabetes.48.9.1794 · DOI · Paper page
- Ueta, 2005, Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats, Life Sci, 76, 2655, 10.1016/j.lfs.2004.09.038 · DOI
- Ferrannini, 2021, Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility, Diabetes Res Clin Pract, 175, 108796, 10.1016/j.diabres.2021.108796 · DOI
- Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
- Hennekens, 2010, Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus, Contemp Clin Trials, 31, 411, 10.1016/j.cct.2010.06.001 · DOI
- Savarese, 2019, Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality, Circulation, 139, 1458, 10.1161/CIRCULATIONAHA.118.038339 · DOI
- Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492 · DOI · Paper page
- 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 · DOI · Paper page
- Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 380, 347, 10.1056/NEJMoa1812389 · DOI · Paper page
- Furtado, 2019, Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction, Circulation, 139, 2516, 10.1161/CIRCULATIONAHA.119.039996 · DOI · Paper page
- Zelniker, 2020, Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58, Eur J Heart Fail
- Bajaj, 2020, Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analysis from the DECLARE-TIMI 58 trial, Diabetes Obes Metab, 22, 1122, 10.1111/dom.14011 · DOI
- Kato, 2019, Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus, Circulation, 139, 2528, 10.1161/CIRCULATIONAHA.119.040130 · DOI · Paper page
- Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
- Ohkuma, 2020, Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program, Diabetes Obes Metab, 22, 530, 10.1111/dom.13920 · DOI
- Bhatt, 2020, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med, 16
- Cavender, 2018, SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL, J Am Coll Cardiol, 71, 2497, 10.1016/j.jacc.2018.01.085 · DOI · Paper page
- Ryan, 2018, Diabetes Obes Metab, 20, 2585, 10.1111/dom.13424 · DOI · Paper page
- Becher, 2021, Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry, Eur J Heart Fail
- Scheen, 2018, Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors, Circ Res, 122, 1439, 10.1161/CIRCRESAHA.117.311588 · DOI · Paper page
- Monami, 2018, Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials, Diabetes Obes Metab, 20, 1213, 10.1111/dom.13221 · DOI
- Cowie, 2020, SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control, Nat Rev Cardiol, 17, 761, 10.1038/s41569-020-0406-8 · DOI · Paper page
- Ferrannini, 2018, Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data, Clin Sci (Lond), 132, 2003, 10.1042/CS20171374 · DOI
- Ferrannini, 2012, SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects, Nat Rev Endocrinol, 8, 495, 10.1038/nrendo.2011.243 · DOI · Paper page
- Ridderstråle, 2014, Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, Lancet Diabetes Endocrinol, 2, 691, 10.1016/S2213-8587(14)70120-2 · DOI · Paper page
- Griffin, 2020, Empagliflozin in heart failure: diuretic and cardiorenal effects, Circulation, 142, 1028, 10.1161/CIRCULATIONAHA.120.045691 · DOI · Paper page
- Jensen, 2021, Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol, 9, 106, 10.1016/S2213-8587(20)30382-X · DOI
- Inzucchi, 2015, SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials, Diab Vasc Dis Res, 12, 90, 10.1177/1479164114559852 · DOI · Paper page
- Ferrannini, 2016, Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes, Diabetes, 65, 1190, 10.2337/db15-1356 · DOI · Paper page
- Lee, 2017, Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts, Free Radic Biol Med, 104, 298, 10.1016/j.freeradbiomed.2017.01.035 · DOI · Paper page
- Verma, 2019, Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial, Circulation, 140, 1693, 10.1161/CIRCULATIONAHA.119.042375 · DOI · Paper page
- Weber, 2003, Dynamic regulation of sodium/calcium exchange function in human heart failure, Circulation, 108, 2224, 10.1161/01.CIR.0000095274.72486.94 · DOI · Paper page
- Yokoyama, 2000, Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium, J Am Coll Cardiol, 36, 534, 10.1016/S0735-1097(00)00730-0 · DOI
- Padan, 2016, Sodium-proton (Na(+)/H(+)) antiporters: properties and roles in health and disease, Met Ions Life Sci, 16, 391
- Trum, 2020, Empagliflozin inhibits Na(+)/H(+) exchanger activity in human atrial cardiomyocytes, ESC Heart Fail, 10.1002/ehf2.13024 · DOI
- Yurista, 2019, Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction, Eur J Heart Fail, 21, 862, 10.1002/ejhf.1473 · DOI · Paper page
- Cappetta, 2020, Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium, Pharmacol Res Jul, 157, 104781, 10.1016/j.phrs.2020.104781 · DOI · Paper page
- Fernandes, 2021, Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials, Heart Rhythm, 18, 1098, 10.1016/j.hrthm.2021.03.028 · DOI · Paper page
- Liu, 2008, Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching, Circ Res, 103, 279, 10.1161/CIRCRESAHA.108.175919 · DOI · Paper page
- Baartscheer, 2017, Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
- Young, 2021, Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a normoglycemic mouse model of cardiac pressure overload, Front Physiol, 12, 738594, 10.3389/fphys.2021.738594 · DOI
- Pitt, 2021, Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?, Circulation, 144, 4, 10.1161/CIRCULATIONAHA.121.054442 · DOI
Cited by
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Metadata
- Authors
- Ferrannini, G., Savarese, G., & Cosentino, F.
- Venue
- Heart Failure Clinics
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 18
- Issue
- 4
- Pages
- 551-559
- ISSN
- 1551-7136
- Cited by
- 13
- References
- 23
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Eli Lilly and Company
- Novo Nordisk
- Familjen Erling-Perssons Stiftelse
- Pfizer
- Vetenskapsrådet
- Boston Scientific Corporation
- AstraZeneca
- Servier
- Merck Sharp and Dohme
- Novartis
- Cytokinetics
- Bristol-Myers Squibb
- Hjärt-Lungfonden
- Medtronic
- Boehringer Ingelheim
- Roche
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.